A medical elastomer pump and an elastomeric membrane for use in infusion therapy. The elastomeric membrane forms a pump volume for receiving and delivering a medical fluid. In a filled state of the pump volume, in which the pump volume is filled at least in part with the medical fluid, the elastomeric membrane is resiliently stretched. The resiliently stretched elastomeric membrane applies a delivery pressure onto the pump volume for delivering the medical fluid. The elastomeric membrane has a plurality of bulge portions which, at least in the filled state, are convex, each forming a bulge. The bulges each form a pump volume portion of the pump volume.

Disclosed are examples of reservoir and reservoir systems usable with a wearable drug delivery device. An example reservoir may include a flexible component coupled to a shell component. The shell component may include drainage channels to facilitate extraction of the liquid drug from the reservoir. A reservoir system example may include an exoskeleton configured around a flexible reservoir to guide the expansion and collapse of the flexible reservoir. Alternatively, one or more rigid panels may be coupled to corresponding flat surfaces of the flexible reservoir to guide the expansion and collapse of the flexible reservoir. A further reservoir example may include a flexible thin film reservoir having peel-able restraints configured to seal off corresponding sections of the reservoir, sequentially break, enabling the liquid drug to sequentially fill corresponding sections in a controlled and predicable manner. A wearable drug delivery device example suitable for utilizing the described examples is provided.

Disclosed are examples of reservoir and reservoir systems usable with a wearable drug delivery device. An example reservoir may include a flexible component coupled to a shell component. The shell component may include drainage channels to facilitate extraction of the liquid drug from the reservoir. A reservoir system example may include an exoskeleton configured around a flexible reservoir to guide the expansion and collapse of the flexible reservoir. Alternatively, one or more rigid panels may be coupled to corresponding flat surfaces of the flexible reservoir to guide the expansion and collapse of the flexible reservoir. A further reservoir example may include a flexible thin film reservoir having peel-able restraints configured to seal off corresponding sections of the reservoir, sequentially break, enabling the liquid drug to sequentially fill corresponding sections in a controlled and predicable manner. A wearable drug delivery device example suitable for utilizing the described examples is provided.

A system and method for correcting a volume of fluid delivered by a fluid injector during an injection procedure is described. The method included determining and compensating for a volume factor associated with compliance of the fluid injector system and correcting for the volume by one of over-driving the distance that the drive member travels in a fluid reservoir, under-driving the distance that the drive member travels in the fluid reservoir, or lengthening or shortening a fluid delivery time.

A system and method for correcting a volume of fluid delivered by a fluid injector during an injection procedure is described. The method included determining and compensating for a volume factor associated with compliance of the fluid injector system and correcting for the volume by one of over-driving the distance that the drive member travels in a fluid reservoir, under-driving the distance that the drive member travels in the fluid reservoir, or lengthening or shortening a fluid delivery time.

A disease management system including a medication delivery pump configured to deliver a medication from a medication pouch to a patient. The medication delivery pump may include one or more plungers configured to interrupt a flow path of medication from a medication reservoir to a patient, one or more muscle wires, and one or more disc shaped springs. The one or more muscle wires and disc shaped springs may be configured to move the one or more plungers to interrupt and uninterrupt the flow path of medication towards a patient from a medication pouch.

A disease management system including a medication delivery pump configured to deliver a medication from a medication pouch to a patient. The medication delivery pump may include one or more plungers configured to interrupt a flow path of medication from a medication reservoir to a patient, one or more muscle wires, and one or more disc shaped springs. The one or more muscle wires and disc shaped springs may be configured to move the one or more plungers to interrupt and uninterrupt the flow path of medication towards a patient from a medication pouch.

Embodiments provide devices, preparations and methods for delivering therapeutic agents (TAs) such as clotting factors (CFs, e.g., Factor 8) within the GI tract. Many embodiments provide a swallowable device e.g., a capsule for delivering TAs into the intestinal wall (IW). Embodiments also provide TA preparations configured to be contained within the capsule, advanced from the capsule into the IW and/or surrounding tissue (ST) and degrade to release the TA into the bloodstream to produce a therapeutic effect (e.g., improved clotting). The preparation can be operably coupled to delivery means having a first configuration where the preparation is contained in the capsule and a second configuration where the preparation is advanced out of the capsule into the IW or ST (e.g., the peritoneal cavity). Embodiments are particularly useful for delivery of CFs for treatment of clotting disorders (e.g., hemophilia) where such CFs are poorly absorbed and/or degraded within the GI tract.

Embodiments provide devices, preparations and methods for delivering therapeutic agents (TAs) such as clotting factors (CFs, e.g., Factor 8) within the GI tract. Many embodiments provide a swallowable device e.g., a capsule for delivering TAs into the intestinal wall (IW). Embodiments also provide TA preparations configured to be contained within the capsule, advanced from the capsule into the IW and/or surrounding tissue (ST) and degrade to release the TA into the bloodstream to produce a therapeutic effect (e.g., improved clotting). The preparation can be operably coupled to delivery means having a first configuration where the preparation is contained in the capsule and a second configuration where the preparation is advanced out of the capsule into the IW or ST (e.g., the peritoneal cavity). Embodiments are particularly useful for delivery of CFs for treatment of clotting disorders (e.g., hemophilia) where such CFs are poorly absorbed and/or degraded within the GI tract.

Apparatus and methods for monitoring and delivering a cell suspension. In certain examples, the apparatus comprises a reservoir containing the cell suspension, a cannula, and a liquid transfer mechanism configured to transfer the cell suspension from the reservoir to the cannula. The apparatus can also comprise an agitation mechanism to agitate the cell suspension, and a monitoring device to quantify a concentration of cells transferred from the reservoir to the cannula.